425: Enfusion and Clearwater Analytics Merger Faces Lawsuits, Supplemental Disclosures Released

Enfusion releases supplemental disclosures related to its pending acquisition by Clearwater Analytics, addressing stockholder lawsuits and updating financial projections.

Summary

• Enfusion, Inc. has filed a Form 8-K report regarding its pending acquisition by Clearwater Analytics Holdings, Inc.
• The report supplements a definitive proxy statement/prospectus filed earlier, addressing stockholder lawsuits and demand letters alleging disclosure deficiencies.
• To avoid further legal expenses and business delays, Enfusion is voluntarily providing additional disclosures related to the claims and updated disclosures on tax matters.
• The supplemental disclosures include revisions to financial projections, background information on the transaction, and Goldman Sachs' financial analyses.
• Two lawsuits have been filed in the Supreme Court of the State of New York, County of New York, alleging misrepresentations and omissions in the proxy statement/prospectus.
• Fourteen demand letters from purported stockholders have also been received, raising similar concerns.
• The special meeting of Enfusion stockholders to vote on the merger is scheduled for April 17, 2025.
• The merger agreement, dated January 10, 2025, outlines the acquisition of Enfusion by Clearwater through a series of mergers.
• The supplemental disclosures amend sections of the proxy statement/prospectus related to financial projections, the background of the transactions, and the opinion of the Special Committee's financial advisor.
• The supplemental disclosures include additional rows to the 10-year profit & loss table, providing updated revenue, Adjusted EBITDA, Adjusted EBIT, NOPAT, and Unlevered Free Cash Flow projections from Q4 2024E to 2034E.
• The supplemental disclosures include additional details on the Special Committee's review of strategic alternatives and interactions with Clearwater and other parties.
• The supplemental disclosures include additional details on Goldman Sachs' financial analyses, including the illustrative discounted cash flow analysis, present value of future share price analysis, and selected precedent transactions analysis.
• The supplemental disclosures include a discussion of the potential impact of the decline in the value of Clearwater Common Stock on the continuity of interest requirement for the merger to qualify as a reorganization.
• If the merger fails to qualify as a reorganization, the receipt of the merger consideration in exchange for Enfusion Common Stock would be a taxable transaction to holders of Enfusion Common Stock for U.S. federal income tax purposes.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company is addressing concerns and providing more information, the existence of lawsuits and the potential for a taxable event temper any positive outlook.

Positives

• Enfusion is proactively addressing stockholder concerns by providing supplemental disclosures.
• The company is aiming to avoid further legal expenses and business delays.
• Detailed financial projections are provided, offering insights into the company's expected future performance.
• The company is providing additional information to its stockholders.

Negatives

• The existence of stockholder lawsuits and demand letters indicates potential dissatisfaction with the initial disclosures.
• The decline in Clearwater's stock value introduces uncertainty regarding the tax implications of the merger.
• The potential for a taxable transaction for Enfusion stockholders if the merger fails to qualify as a reorganization is a negative outcome.

Risks

• The lawsuits and demand letters could delay or even prevent the completion of the merger.
• The decline in Clearwater's stock value could lead to the Second Merger not being completed.
• Failure to meet the continuity of interest requirement could result in a taxable transaction for Enfusion stockholders.
• The integration of Enfusion's operations and technology with those of Clearwater may present challenges.

Future Outlook

The document provides forward-looking financial projections for Enfusion through 2034, but these are subject to various risks and uncertainties, including the successful completion of the acquisition by Clearwater Analytics.

Management Comments

• Enfusion believes that the disclosures set forth in the Definitive Proxy Statement/Prospectus comply fully with all applicable law and denies the allegations in the Matters described above.
• Enfusion and the other named defendants specifically deny all allegations in the complaints, including the allegations that any additional disclosure was or is required or material.

Industry Context

The acquisition of Enfusion by Clearwater Analytics reflects a trend of consolidation in the financial technology sector, as companies seek to expand their product offerings and market reach.

Comparison to Industry Standards

• The selected precedent transactions analysis includes deals such as Cloudera, Inc. acquired by Clayton, Dubilier & Rice, LLC & Kohlberg Kravis Roberts & Co. L.P. at 5.2x EV/NTM Revenue and Qualtrics International Inc. acquired by Silver Lake Partners & Canada Pension Plan Investment Board at 7.1x EV/NTM Revenue.
• Other comparable transactions include Simcorp A/S acquired by Deutsche Borse AG at 6.6x EV/NTM Revenue and New Relic, Inc. acquired by Francisco Partners Management, L.P. and TPG Capital Management, L.P. at 5.8x EV/NTM Revenue.
• The analysis also considers transactions such as Alteryx, Inc. acquired by Clearlake Capital Group, L.P. & Insight Partners at 4.3x EV/NTM Revenue and Envestnet, Inc. acquired by Bain Capital, LLC at 4.9x EV/NTM Revenue.

Legal Proceedings

• Two complaints have been filed as individual actions in the Supreme Court of the State of New York, County of New York: Scott v. Enfusion, Inc. et al., No. 652094/2025 (N.Y. Sup. Ct.) and Ballard v. Enfusion, Inc. et al., No. 652130/2025 (N.Y. Sup. Ct.).
• The Complaints generally allege that the proxy statement/prospectus misrepresents and/or omits certain purportedly material information.
• The Complaints assert claims under New York common law for negligent misrepresentation and concealment and negligence against Enfusion and the members of the Enfusion board of directors.
• The Complaints seek, among other things, to enjoin the consummation of the Mergers, damages if the Mergers are consummated, and attorneys fees.

Stakeholder Impact

• Shareholders face uncertainty regarding the merger's completion and potential tax implications.
• Employees may experience changes as a result of the integration of Enfusion and Clearwater.
• Customers could benefit from the combined product offerings of the two companies.

Next Steps

• Enfusion stockholders will vote on the proposed merger at a special meeting on April 17, 2025.
• Clearwater and Enfusion will continue to work towards satisfying the closing conditions of the merger agreement.
• The companies will address the pending lawsuits and demand letters.

Key Dates

Keywords

Merger, Acquisition, Enfusion, Clearwater Analytics, Proxy Statement, Financial Projections, Stockholder Lawsuits, Supplemental Disclosures